Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin)

Jonathan Shahar, Robert L. Avery, Gad Heilweil, Adiel Barak, Esther Zemel, Geoffrey P. Lewis, Patrick T. Johnson, Steven K. Fisher, Ido Perlman, Anat Loewenstein*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE: Intravitreal bevacizumab (Avastin; Genentech Inc., San Francisco, CA) is a new treatment for age-related macular degeneration. The aim of this study was to evaluate retinal penetration and toxicity of bevacizumab. METHODS: Ten albino rabbits were injected intravitreally with 0.1 mL (2.5 mg) of Avastin into one eye and 0.1 mL saline into the fellow eye. The electroretinogram (ERG) was recorded after 3 hours, 3 days, and 1, 2, and 4 weeks. The visual evoked potential (VEP) was recorded after 4 weeks. Confocal immunohistochemistry was used to assess retinal penetration. RESULTS: The ERG responses of the control and experimental eyes were similar in amplitude and pattern throughout the follow-up period. The flash VEP responses of the experimental eyes were of normal pattern and amplitude and did not differ from those recorded by stimulation of the control eye alone. Full thickness retinal penetration was present at 24 hours and was essentially absent at 4 weeks. CONCLUSIONS: Bevacizumab was found to be nontoxic to the retina of rabbits based on electrophysiologic studies. Full thickness retinal penetration may explain observed clinical effects of intravitreal bevacizumab. Although it is difficult to directly extrapolate to humans, our study supports the safe use of intravitreal bevacizumab injection.

Original languageEnglish
Pages (from-to)262-269
Number of pages8
JournalRetina
Volume26
Issue number3
DOIs
StatePublished - Mar 2006

Keywords

  • Avastin
  • Bevacizumab
  • Intravitreal injection
  • Retinal toxicity

Fingerprint

Dive into the research topics of 'Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin)'. Together they form a unique fingerprint.

Cite this